• North Carolina Advances in Stem Cell Therapy for Lung Diseases Could Lead to Clinical Trial Soon
  • Prometic, SRAM to Jointly Advance 3 Fibrosis, Scleroderma Therapies for Booming Chinese Market
  • Vaccination Against Lung Pathogens Vital for People with Lung Disease, American Lung Association Reminds
  • Pulmonary Fibrosis Awareness Month Kicks Off with PFF Walk in Chicago
  • FDA Approves Teva’s QVAR RediHaler Asthma Maintenance Inhaler
  • Genentech’s Alecensa Granted Priority Review for First-line Treatment of ALK-positive Advanced NSCLC
  • Potential Therapy, GLPG1690, Seen to Halt Worsening of Lung Fibrosis in Phase 2 Trial
  • Pamrevlumab Can Slow Progression of Pulmonary Fibrosis, Phase 2 Clinical Trial Suggests
  • Three Lakes Partners Now Accepting Submissions for $1M IPF Healthcare Challenge
  • Physical Activity May Predict Mortality Risk Among IPF Patients, German Researchers Say
  • Aridis Is Enrolling Patients in Pivotal Trial of Its Antibiotic-resistant Pneumonia Therapy Aerucin
  • FDA OKs Trial Design of INOpulse Device as Treatment for Pulmonary Hypertension Linked to Lung Disease

Pulmonary Fibrosis

Asthma

Bronchiectasis

BRONCHIOLITIS

CHRONIC BRONCHITIS

COPD

 CYSTIC FIBROSIS

EMPHYSEMA

IDIOPATHIC PULMONARY FIBROSIS

LUNG CANCER

PNEUMONIA

PULMONARY HYPERTENSION

SCLERODERMA